Modality
Multispecific
MOA
PARPi
Target
JAK2
Pathway
Apoptosis
CLL
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
~Sep 2017
→ ~Dec 2018
Phase 2
~Mar 2019
→ ~Jun 2020
Phase 3
~Sep 2020
→ ~Dec 2021
NDA/BLA
Mar 2022
→ Feb 2031
NDA/BLACurrent
NCT06292786
1,270 pts·CLL
2024-02→2031-02·Recruiting
NCT04399386
139 pts·CLL
2022-03→TBD·Completed
1,409 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-02-044.8y awayPh3 Readout· CLL
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
NDA/BLA
Complet…
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2031-02-04 · 4.8y away
CLL
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06292786 | NDA/BLA | CLL | Recruiting | 1270 | HAM-D |
| NCT04399386 | NDA/BLA | CLL | Completed | 139 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| UTH-9370 | United Therapeutics | NDA/BLA | TIGIT |